Prerpints.org logo
Preprint
Review

Therapeutic Potential of Various Intermittent Fasting Regimens in Alleviating Type 2 Diabetes Mellitus and Prediabetes: A Comprehensive Review

This version is not peer-reviewed.

Submitted:

17 June 2024

Posted:

17 June 2024

You are already at the latest version

A peer-reviewed article of this preprint also exists.

Abstract
: Intermittent fasting has drawn significant interest in the clinical research community due to its potential to address metabolic complications such as obesity and type 2 diabetes mellitus. Various intermittent fasting regimens include alternate-day fasting (24 hours of fasting followed by 24 hours of eating), time-restricted fasting (fasting for 14 hours and eating within a 10-hour window), and the 5:2 diet (fasting for two days and eating normally for the other five days). Intermittent fasting is associated with a reduced risk of type 2 diabetes mellitus-related complications and can slow their progression. The increasing global prevalence of type 2 diabetes mellitus highlights the importance of early management. Since prediabetes is a precursor to type 2 diabetes mellitus, understanding its progression is essential. However, the long-term effects of intermittent fasting on prediabetes are not yet well understood. Therefore, this review aims to comprehensively compile existing knowledge on the therapeutic effects of intermittent fasting in managing type 2 diabetes mellitus and prediabetes.
Keywords: 
Intermittent fasting
;  
Type 2 diabetes mellitus
;  
Prediabetes
;  
HbA1c
;  
Glucose tolerance
Subject: 
Public Health and Healthcare  -   Public Health and Health Services

1. Introduction

Intermittent fasting (IF) is a broad term describing several eating regimens in which individuals alternate long periods of normal calorie intake with periods of minimal or no energy intake [1]. In 1935, McCay elucidated the correlation between calorie restriction and lifespan or longevity [2]. Since then, studies have extensively investigated calorie restriction, evolving into the practice of intermittent fasting [1,3,4,5]. Research findings have highlighted the use of intermittent fasting and its efficacy in metabolic-related disorders [1,3,4,5,6]. Several intermittent fasting protocols have been recognized for their capacity to mitigate metabolic disorders [7,8,9,10,11,12,13,14,15].
The IF protocols include dietary approaches that involve alternating eating periods with either fasting by restricting calorie intake or zero calorie intake during the fasting period [6]. The timing of fasting and feeding periods varies among different IF protocols, such as the 5:2 diet, alternate-day fasting, and time-restricted feeding [16]. The 5:2 fasting diet is a dietary regimen where individuals eat without restrictions for five days, followed by two days per week during which they consume a very low-calorie diet (less than 800 calories per day) [17]. Alternate day fasting (ADF) involves alternating between a 24-hour fasting period, during which individuals consume less than 25% of their usual energy needs, and a 24-hour eating period, where they can eat normally [15]. Time-restricted feeding (TRF) is an IF protocol with a specified time of prolonged fasting practiced by adhering to 16 hours of abstinence from food and 8 hours of food intake within 24 hours [6]. IF has gained popularity in body weight management and alleviating metabolic-related disorders [18,19]. Therefore, this review aims to comprehensively synthesize existing knowledge on the therapeutic effects of intermittent fasting on the management of T2DM and prediabetes, providing a critical overview of its current state of understanding. The next section is an overview of the effects of IF on metabolic complications.

2. Effects of IF on Metabolic Complications

Obesity has become a significant concern, contributing to around 62% per 100,000 individuals in the population in 2019 [20]. Epidemiological studies utilize Body Mass Index (BMI) as a tool to identify individuals who are either obese or overweight [21,22]. Obesity has been correlated with the development of several physiological disorders, including type 2 diabetes, inflammation, cardiovascular disease, hypertension, dyslipidemia, non-alcohol fatty liver disease, and insulin resistance [21,22]. Energy imbalance, leading to excess body fat (≥20%) defines obesity [23,24,25]. Therapeutic interventions like fasting and the use of antidiabetic medications have been linked to substantial weight loss, suggesting improvements in clinical factors associated with metabolic complications [26,27,28,29].
The fasting regimens mentioned have demonstrated efficacy in eliciting favorable metabolic alterations. The changes include improved glucose control, reduced glycogen storage, release of fatty acids and ketones, decreased levels of leptin, and increased levels of adiponectin [1,30,31,32]. In overweight or obese adults, IF has reported a decrease in BMI, body weight, waist circumference, and fat mass [3,17,33,34,35]. Interestingly, a study conducted in obese middle-aged female Wistar rats found that ADF and TRF did not lead to reductions in blood lipid profiles, adiposity, or insulin resistance. Instead, these dietary interventions increased inflammatory biomarkers, potentially elevating the risk of obesity-associated comorbidities [36]. Other studies reported differently on outcomes of insulin resistance, blood lipids, adiposity, inflammatory markers, and glycemic control upon IF adherence [37,38].
Insulin resistance (IR) occurs when the main target tissues for insulin action in glucose metabolism do not respond to insulin as they should due to chronic energy surplus [39]. Therefore, weight loss is essential for regulating disordered glucose and lipid metabolism, notably insulin resistance and hyperinsulinemia caused by central obesity [30,31,40]. Furthermore, insulin resistance has been implicated in T2DM [41,42]. T2DM is a chronic hyperglycaemic condition triggered by a preceding loss of β- cell insulin secretion and insulin resistance [43]. The onset of a metabolic switch brought on by fasting is due to the negative energy balance caused by the depletion of glycogen stores and metabolized fatty acids.
The metabolic switch from using glucose to fatty acid-derived ketones represents a gradual change in the metabolism from lipid/cholesterol synthesis and fat storage to fat mobilization through fatty acid oxidation and fatty-acid-derived ketones. As a result, the metabolic switch aids in maintaining muscle mass and its function, which promotes weight loss [16]. During fasting, ketones continuously increase while glucose decreases, and this is inverse to the postprandial state, where glucose levels increase while ketones diminish [44]. The outcomes of the metabolic transition observed during fasting may ameliorate insulin sensitivity and glycaemic regulation detected in persons with non-insulin-dependent diabetes.

3. Type 2 Diabetes Mellitus

Diabetes continues to be a significant contributor to mortality and morbidity rates globally [45]. It is expected that 578 million people will have diabetes by 2030, increasing by 51% (700 million) by 2045, from 463 million in 2019 [45,46]. Approximately 90% to 95% of all diabetes diagnoses are classified as type 2 diabetes mellitus [47]. According to both the American Diabetes Association (ADA) and World Health Organisation (WHO), diabetes can be diagnosed if a person has a fasting plasma glucose level of ≥126 mg/dL (7.0 mmol/L) after fasting for at least 8 hours, a plasma glucose level of ≥200 mg/dL (11.1 mmol/L) during a 75g oral glucose tolerance test (OGTT) [48]. The ADA also uses a glycated hemoglobin (HbA1c) level of at least 6.5% (48 mmol/mol Hb) to diagnose diabetes [49,50]. Both ADA and WHO approves diagnosing glucose in plasma, although it can also be measured in serum and whole blood [51,52].
The escalating rise in the prevalence of T2DM underscores the significance of comprehending its etiology and pathogenesis [53]. T2DM is a multifactorial disorder characterized by a sophisticated interplay of genetic and environmental elements. Genetic factors play a crucial role in the development of T2DM by influencing impaired insulin secretion and insulin resistance [54]. Individuals with T2DM exhibit dysfunctional pancreatic beta cells, leading to compromised insulin secretion, and hindered insulin action due to the presence of insulin resistance [54,55]. The intricate genetic landscape interacts dynamically with environmental factors, such as obesity, dietary patterns, elevated stress levels, and the aging process [54]. The convergence of these genetic and environmental components creates a conducive setting for the initiation and progression of T2DM and its related complications [56,57,58,59,60,61].

4. Conventional Management of T2DM

4.1. Insulin Therapy

Insulin therapy serves as an injectable medication for diabetes mellitus [62]. The use of exogenous insulin is primarily employed to regulate blood glucose levels and alleviate symptoms of T2DM by replenishing or complementing the body's natural insulin production from the pancreas [62,63]. Insulin therapy directly activates the insulin receptor, leading to increased glucose uptake, decreased production of glucose by the liver, and decreased breakdown of fats [64]. Hence, insulin therapy is positively associated with a decrease in fasting glucose levels, glucose tolerance, and HbA1c [65,66,67]. Nevertheless, the consequence of diminishing fat breakdown may lead to the buildup of triglycerides in both the bloodstream and fatty tissues, resulting in an elevated likelihood of gaining weight [68]. The weight gain mechanism in insulin-treated T2DM involves factors such as hypoglycemia-associated snacking, inhibited glucose excretion (glycosuria), and decreased metabolic rates [69].

4.2. Glucagon-Like Peptide-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) is a hormone primarily located in the gastrointestinal tract, secreted in response to the ingestion of nutrients (carbohydrates, and fats) [70]. GLP-1Ra functions by controlling elevated blood glucose levels after meals by increasing the release of insulin from the beta cells [71]. These drugs have been associated with decreased FG, HbA1c and GT [72,73,74]. Additional benefits encompass suppressing glucagon release, delaying stomach emptying, promoting insulin release, and reducing appetite [70,71,75]. The disadvantages of using GLP-1Ra have been associated not only with gastrointestinal effects but also with gallbladder diseases, attributed to reduced gallbladder refilling [76,77].

4.3. Dipeptidyl Peptidase-4 Inhibitors

Dipeptidyl peptidase-4 inhibitors (DPP4i) function by inhibiting the activity of DPP-4 [78]. DPP4i enhances insulin secretion from pancreatic beta cells in a glucose-dependent manner through the action of GLP-1, while concurrently decreasing glucagon release from alpha cells [75,79]. DPP-4 inhibitors have been demonstrated to effectively lower FG, postprandial glucose, and HbA1c levels while maintaining a low risk of hypoglycemia. [79,80]. Nonetheless, there has been a noted rise in the occurrence of acute pancreatitis linked to their utilization [78,81].

4.4. Sodium-Glucose Co-Transport 2 Inhibitors

Sodium-glucose co-transport (SGLT)-2 is a kidney transporter responsible for the reabsorption of glucose from the renal filtrate, thus hindering the excretion of glucose through urine [82]. SGLT2 inhibitors represent a newer class of antihyperglycemic medications that function independently of insulin, providing effects beyond simply lowering glucose levels. These drugs promote urinary glucose excretion and natriuresis by inhibiting the reabsorption of glucose and sodium in the proximal tubule of the kidney [82]. This class of antidiabetic drugs has been revealed to reduce HbA1c levels (~0.51% -1.01%), FG, and postprandial glucose [83,84,85]. The disadvantages related to the administration of SGLT2i include increased risk of urinary tract infection, genital infection, and lower limb amputation [86,87].

4.5. Biguanide (Metformin)

Metformin, a commonly prescribed antidiabetic drug, is widely acknowledged as a biguanide with properties that enhance insulin sensitivity [88]. Metformin improves glucose utilization and sensitivity to insulin in tissues outside the liver [89]. At therapeutic doses, metformin utilizes multiple mechanisms to reduce blood glucose levels [90]. This antidiabetic drug has been reported to improve GT, HbA1c, and FG [90]. While the liver is the main target organ for metformin action, there is also evidence suggesting involvement of the intestines [91].
Metformin's effects in the gastrointestinal tract encompass increased intestinal absorption and lactate generation, elevated concentrations of GLP-1, and modification of bile acid pools, consequently impacting the microbiome's composition [91]. However, the use of metformin has been associated with the occurrence of vitamin B12 deficiency, which may contribute to the manifestation of diabetic neuropathy symptoms [88,92]. Furthermore, changes in gut flora, alterations in gut motility, competitive inhibition of absorption, and impairment of calcium-dependent membrane actions in the terminal ileum have been proposed as mechanisms contributing to the development of vitamin B12 deficiency associated with metformin use [92,93]. Regular monitoring of vitamin B12 levels and appropriate supplementation may be necessary for individuals on long-term metformin therapy to address this potential concern.
Table 1. Shows the different types of antidiabetic drugs and their mode of action, effects on glucose parameters, and shortfalls.
Table 1. Shows the different types of antidiabetic drugs and their mode of action, effects on glucose parameters, and shortfalls.
Types of antidiabetic drug(s) Mode of Action Effects on glucose parameters Shortfall(s)
Insulin therapy
  • Direct glucose-lowering effect.
  • Facilitation of glucose uptake by cells.
  • Inhibition of hepatic glucose production.
  • Promotion of glycogen synthesis.
  • Reduced FG,
  • Reduced GT
  • Reduced HbA1c
  • Weight gain
GLP-1RA
  • Slowing of gastric emptying
  • Suppression of glucagon secretion
  • Enhancement of glucose-dependent insulin secretion
  • Improvement in Beta Cell Function
  • Reduction of Appetite and Food Intake
  • Reduced FG,
  • Reduced GT
  • Reduced HbA1c
  • Gastrointestinal effects
  • Gallbladder disease
DPP4i
  • Inhibition of DPP-4 enzyme
  • Reduction in Blood Glucose Levels
  • Prolongation of incretin hormone activity
  • Weight management
  • Reduced FG
  • Reduced GT
  • Reduced HbA1c
  • Acute pancreatitis
SGL2i
  • Inhibition of SGLT2 in the kidneys
  • Increased urinary glucose excretion.
  • Reduction in blood glucose levels
  • Caloric loss and weight reduction.
  • Osmotic Diuresis.
  • Reduced FG,
  • Reduced GT
  • Reduced HbA1c
  • Urinary tract infection,
  • Genital infection
  • Lower limb amputation
Metformin
  • Enhanced peripheral glucose uptake.
  • inhibition of intestinal glucose transport.
  • Improvement of lipid metabolism.
  • Reduced FG,
  • Reduced GT
  • Reduced HbA1c
  • Vitamin B12 deficiency
  • Lactic acidosis

5. Lifestyle Intervention

Lifestyle intervention is widely recognized for its effectiveness in reducing the risks associated with T2DM [94]. Lifestyle intervention has been linked to reduced occurrences of T2DM and lower incidences of cardiovascular events, microvascular complications, cardiovascular mortality, and all-cause mortality, leading to increased life expectancy in patients with IGT [94]. The application of lifestyle intervention has also been reported as cost-effective for patients who adhere to it [95]. A DPP 10-year follow-up diabetes study showed that at 2.8 years, there was a 58% reduction in the incidence of diabetes among high-risk adults with lifestyle intervention, which was superior to the 31% reduction observed with metformin [96]. On the initial year visit, a mean weight loss of 7kg was observed [96]. This confirms the superiority of lifestyle intervention over the established first-line drug, metformin. Intervention strategies encompass physical activity, exercise, and dietary plans [97].

5.1. Dietary Intervention

Dietary intervention encompasses a banting diet, a ketogenic diet, and a Mediterranean diet [98,99,100]. The Banting diet is characterized by high protein intake, whereas the ketogenic diet focuses on low carbohydrates, high fat, and adequate protein, and the Mediterranean diet emphasizes a higher consumption of vegetables [98,100,101]. To achieve long-term weight loss, factors such as meal timing and macronutrient composition must counteract compensatory changes in hunger, cravings, and ghrelin suppression mechanisms. These factors can serve as a boost for weight gain after a previous loss [102]. However, dietary intervention has been linked with positive effects on FG, GT, and HbA1c [103,104,105]. Abstinence from food or fasting entails the breakdown of lipids, carbohydrates, and proteins to regulate plasma glucose within the normal range. Progressive accumulation of fats in the pancreas and liver may lead to dysfunction of beta cells, resulting in hyperglycemia. This condition can be reversed by reducing fats in the liver and pancreas [5].

5.2. Increased Physical Activity

Physical activity has demonstrated antidiabetic effects in individuals with T2DM [106]. Physical activity consists of body movements driven by the contraction of skeletal muscles, resulting in increased energy expenditure [106]. Increased physical activity such as exercise interventions has been implemented to alleviate hyperglycaemia [107]. Research has shown that low- and moderate-intensity exercise can lower FG, GT, and HbA1c levels [108,109]. A qualitative research revealed that obstacles to physical activity can include health issues (like breathing problems), difficulties with time and lifestyle management (such as lack of time and motivation), and various environmental, social, and cultural factors [110].

6. Effect of Intermittent Fasting on T2DM

6.1. Alternate Day Fasting

Many investigations have been carried out to assess the safety and tolerability of alternate day fasting regimens, showing promising clinical outcomes related to T2DM [111,112,113]. Research findings suggest that alternate day fasting can serve as an alternative approach to continuous CR, with superior effects observed in the retention of lean mass [112,114]. The utilization of alternate-day fasting resulted in a significant decrease in total cholesterol and serum triglycerides [115]. Another study, supported by evidence, demonstrated that adherence to alternate-day fasting can positively impact glucose tolerance within 3 weeks via heightened expression of the SIRT1 gene [116]. Despite a notable reduction in total intra-abdominal fat mass, the alternate-day fasting group reported a failure to alleviate diet-induced muscle insulin resistance caused by a high-fat diet [117].
The potential cause may be attributed to a decrease in the expression of GLUT-4 protein in both high-fat ad libitum (HF-AL) and high-fat alternate-day fasting (HF-ADF) rats compared to the Chow group [117]. Conversely, another study showed a positive impact on glycemic control in genetically obese mice undergoing alternate-day fasting, despite the absence of significant weight loss [118]. In mice, fructose-induced resistance was alleviated by a 100% restriction on chow food but allowing ad libitum access to fructose drink during fasting days of alternate day fasting. This group exhibited significant improvements in insulin sensitivity compared to the control group [119]. A study revealed a direct correlation between alterations in body weight and improvements in glycemic control, insulin sensitivity, and insulin secretion in obese males with and without T2DM [120]. Alternate-day fasting produces superior outcomes, specifically a decrease in fasting insulin levels and insulin resistance, compared to continuous CR in individuals with insulin resistance [121].
Alternate fasting has also been associated with adverse effects, including hunger, impaired cognitive function, and irritability, which may diminish within a month of adherence [122,123]. On the contrary, a six-month study found that combining ADF with a low-carbohydrate diet did not result in changes in appetite [124]. This suggests that various alternate day fasting protocols may lead to diverse outcomes upon adherence. Therefore, further research is necessary to assess the impact of different alternate-day fasting approaches on the body's physiological functions.
6.2. 5:2. Fasting Diet
The 5:2 diet regimen may serve as an alternative approach to continuous CR, exhibiting reported comparable efficacy in weight management and glycemic control [125]. A (600 kcal)/day diet has been demonstrated to yield significant improvements in beta cell function and hepatic insulin sensitivity, potentially leading to a reversal of T2DM [126]. A 12-week study comparing consecutive versus non-consecutive fasting days utilizing the 5:2 diet regimen demonstrated significant reductions in weight and glycemic levels among individuals with T2DM [127]. Dietary restriction of energy intake was associated with substantial improvements in various markers, including reductions in HbA1c levels, improved results in OGTT, decreased pancreatic and liver triacylglycerol stores, and lowered FG levels [126]. However, cautious measures may be necessary for continuous VLCD regimens, particularly in managing oral hypoglycemic agents to prevent hypoglycemia [128]. Additionally, VLCDs can pose long-term risks of complications such as micronutrient deficiencies [129]. The 5:2 diet has been associated with significantly lower compliance rates. It has been indicated that this diet often results in significant overcompensation during non-fasting days [130].

6.3. Time-Restricted Feeding

TRF has been documented to exhibit a high adherence rate among participants [131]. This regimen has been shown to positively influence fasting glucose, glucose tolerance, and HbA1c levels in T2DM [132]. The glycemic impacts can be achieved through the Circadian Timing System [133]. Several studies have proven that aligning with the circadian timing system plays a role in positive outcomes upon TRF adherence [134,135,136,137]. Research involving both humans and animals suggests that Early TRF is favored as the superior regimen over late TRF [134,137]. Early TRF has been shown to enhance insulin sensitivity, promote weight loss, and fat oxidation, and help manage glycemic levels [137].

7. Prediabetes

Despite the possibility of correcting prediabetes to normal glucose regulation, it nonetheless imposes a strain [138]. Prediabetes can be characterized by elevated blood glucose levels that do not meet the diagnostic criteria for diabetes [139]. Prediabetes has an asymptomatic characteristic, and this makes it hard to diagnose [140]. The prevalence of prediabetes is increasing year after year, with 5% to 10% of prediabetic people advancing to the fatal T2DM and its related complications [31,140,141]. The diagnostic criteria of prediabetes include FG, IGT, and HbA1c. Regardless of WHO not recognizing HbA1c as a diagnostic criterion for prediabetes. It has been shown that ADA identifies individuals with IFG of 5.6 – 6.9 mmol/L, IGT of 7.8 – 11.0 mmol/L, and HbA1c 5.7 - 6.4 % as prediabetic [142]. The rising prevalence of prediabetes is causing significant concern. Recent research suggests that the global prevalence of prediabetes is expected to exceed 400 million individuals by 2045 [143].
Research has demonstrated that insulin resistance in adipose tissue contributes to the onset of hyperglycemia and associated complications [144,145,146,147]. Insulin resistance in adipose tissue stimulates the increased release of free fatty acids into the bloodstream, facilitating ectopic fat storage [145]. This process induces insulin resistance in the liver and skeletal muscles, culminating in metabolic issues such as elevated glycaemic levels, abnormal lipid levels, hypertension, metabolic syndrome, and NAFLD [144,145,146]. Decreased physical fitness has been linked to increased levels of free fatty acids, reduced insulin clearance, diminished insulin sensitivity in muscles, slightly elevated triglycerides, and decreased levels of HDL cholesterol [146]. Additionally, research indicates that prediabetic individuals with insulin resistance face double the risk of cardiovascular disease compared to prediabetic individuals who do not have insulin resistance [148]. Prompt detection of prediabetes and its associated complications is vital for mitigating the risks it poses to individuals.

7.1. HOMA-IR

The Homeostasis Model Assessment of Insulin Resistance ( HOMA-IR) represents a diagnostic tool used in clinical settings to evaluate the resistance of insulin, calculated as HOMA-IR = (Fasting Insulin (mU/L) × Fasting Glucose (mmol/L)) / 22.5 [149]. Prediabetic individuals prevail in insulin resistance either in the hepatocytes, fatty tissues, or skeletal muscles [150].

8. Prediabetes Management

Irrespective of the current criteria employed for prediabetes diagnosis, the presence of IR, obesity, either IFG, IGT, or both, still poses the risk of progressing to T2DM [21,22,148,151]. Various measures have been utilized to decrease prediabetes prevalence and progression to T2DM. Primary treatments for prediabetes include a combination of lifestyle changes such as weight loss, increased physical activity as well as the use of medications like metformin [152]. Lifestyle changes have demonstrated effectiveness in reducing the risk of developing T2DM, even with less intensive interventions [153].

8.1. Biguanides (Metformin)

Metformin is a medication used for managing both prediabetes and T2DM [90]. Interestingly, research indicates that metformin has beneficial effects on glucose measures such as FG, GT, and HbA1c levels [154,155]. However, using metformin alone is less effective than combining it with other antidiabetic medications or lifestyle changes [155,156]. Furthermore, metformin use is associated with adverse effects such as lactic acidosis, vomiting, and diarrhea [154].

8.2. Lifestyle Modification

A lack of physical activity and obesity significantly contribute to the advancement of T2DM [157]. Physical activity involves the body's movement through the contraction of skeletal muscles, which leads to an elevation in energy expenditure [158]. Increased physical activity such as exercise interventions has been implemented to alleviate prediabetes [107]. Exercise interventions have improved IFG, IR, IGT, HbA1c levels, and weight loss. Exercise is associated with muscle insulin sensitivity [159]. An increase in insulin sensitivity is facilitated by the movement of several GLUT4 transporters to the cell membrane in response to a submaximal insulin stimulus [159]. Thereby promoting glucose tolerance and the reduction of glucose levels in the bloodstream [160].
However, short exercise intervention has been reported to fail to alter HDL-C levels [161]. A multivariate analysis found that the duration of exercise per session is a key predictor of changes in HDL cholesterol levels [162]. Additionally, the efficacy of exercise intervention in raising HDL-C levels has been associated with lower BMI or higher total cholesterol levels [162,163]. Variations in blood glucose levels could be affected by the type of physical activity engaged in, and specific exercise modalities might not be viable options for individuals who are overweight or obese [164]. Therefore, overweight or obese prediabetic individuals need to prioritize weight loss as a preliminary step to enhance their HDL-C levels.
Weight loss strategies often involve dietary interventions, which typically entail reducing calorie intake to manage body weight and address other clinical factors [165]. Very low-calorie restriction has been linked to improvements in beta cell function, leading to the restoration of the first phase of insulin secretion in prediabetic individuals [166]. Studies have reported a reduction in fasting glucose levels, HbA1c, weight loss, increased fasting insulin levels, and improved Homeostatic Model Assessment of Beta-cell Function (HOMA-β) [166,167]. Nevertheless, elevated fasting ghrelin levels have been correlated with an increased risk of weight regain following weight loss [168]. Interestingly, achieving positive metabolic outcomes through intermittent fasting may not necessarily require weight loss [169].

8.3. Intermittent Fasting

Recent research has emphasized the potential of IF as an alternative approach for addressing metabolic factors associated with prediabetes [52,111,169]. Literature has shown the efficacy and safety of ADF and the 5:2 fasting diet in managing prediabetes. While Ingersen and colleagues reported a lack of significant changes in insulin sensitivity or secretion, other studies have suggested that ADF has the potential to decrease body weight, lower fasting insulin levels, improve IFG, reduce postprandial hyperglycemia, and decrease levels of HbA1c [120,121,170]. Furthermore, the 5:2 fasting diet has demonstrated notable efficacy in diminishing body weight, improving insulin sensitivity, and lowering both IFG and HbA1c over a 12-week intervention period [171]. Despite achieving favorable results, the effectiveness of fasting methods in enhancing metabolic factors might fluctuate depending on the duration of fasting or the specific fasting strategies employed. Therefore, this study aims to highlight the benefits of TRF as the standard alternative approach for prediabetes.
A commonly followed approach to TRF involves fasting for 16 hours and consuming meals within an 8-hour window each day (16/8) [172]. Alternatively, individuals may choose to fast for 14 hours and consume meals within a 10-hour window daily (14/10), or they may opt for a 20-hour fasting period followed by a 4-hour window for food consumption (20/4) [173,174]. Clinical studies have been drawn to these approaches due to their effects in regulating T2DM and its associated complications in short term studies [175,176]. A systematic review revealed that the 16/8 and 14/10 fasting methods exhibit similar efficacy in body weight loss [177].
Research has indicated the effectiveness of adhering to a 14/10 fasting regimen in controlling glycemic levels, despite not affecting insulin sensitivity in T2DM [37,178]. TRF has been demonstrated to increase insulin sensitivity, decrease blood glucose levels, reduce fasting insulin, reduce HbA1c levels, and enhance glucose tolerance by stimulating beta cell responsiveness [169,173,175,176,179]. On the contrary, literature has examined the effects of adhering to TRF either early or late in the day. Literature has observed that consuming meals late in the day leads to a suppression of resting energy expenditure, reduced fasting carbohydrate oxidation, and impaired glucose tolerance [180,181]. Meal timing plays a role in weight loss therapy, with delayed lunch consumption being associated with less weight loss compared to eating earlier, regardless of adhering to a hypocaloric diet [182]. Research consistently shows that consuming meals earlier in the day (8 a.m. to 7 p.m.) is notably more effective in reducing body weight, fasting glucose levels, insulin resistance, enhancing insulin response, and decreasing ghrelin levels compared to eating later in the day (12 p.m. to 11 p.m.) [182,183,184]. Thus, early TRF has superior effects on metabolic factors compared to late TRF.

9. Conclusion

The available anti-diabetic medications have demonstrated the potential to improve T2DM and prediabetes. However, significant drawbacks have surfaced, creating an opportunity for alternative approaches. Hence, this comprehensive review provided insights into the therapeutic potential of intermittent fasting in managing prediabetes and T2DM. Intermittent fasting has been evidenced to be beneficial in short-term studies, highlighting its beneficial impacts on metabolic factors. These effects have been investigated in metabolic disorders like obesity and T2DM. Nevertheless, the precise mechanisms through which IF modulates glycemic levels and its enduring influence on gene expression, such as GLUT 4 and IRS1, remain unclear. Additionally, the impact of intermittent fasting on glycemic markers and identifying an optimal IF regimen for prediabetes management is yet to be fully elucidated. Therefore, there is a need for comprehensive, long-term investigations to assess the role of IF in glycemic regulation and its associated gene expression, including examining key regulators such as GLUT 4 and IRS1.

Author Contributions

Conceptualization, S.M., A.K. and A.S.; writing ―original draft preparation, S.M.; writing ―review and editing, A.K. and A.S.; visualization, S.M., A.K. and A.S.; supervision, A.K. and A.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Mattson, M.P.; Longo, V.D.; Harvie, M. Impact of intermittent fasting on health and disease processes. Ageing Res Rev. 2017, 39, 46–58. [Google Scholar] [CrossRef] [PubMed]
  2. McDonald, R.B.; Ramsey, J.J. Honoring Clive McCay and 75 Years of Calorie Restriction Research. The Journal of Nutrition. 2010, 140, 1205–1210. [Google Scholar] [CrossRef] [PubMed]
  3. He, S.; Wang, J.; Zhang, J.; Xu, J. Intermittent Versus Continuous Energy Restriction for Weight Loss and Metabolic Improvement: A Meta-Analysis and Systematic Review. Obesity 2021, 29, 108–115. [Google Scholar] [CrossRef] [PubMed]
  4. Cook, F.; Langdon-Daly, J.; Serpell, L. Compliance of participants undergoing a '5-2' intermittent fasting diet and impact on body weight. Clin Nutr ESPEN. 2022, 52, 257–261. [Google Scholar] [CrossRef]
  5. Taylor, R. Calorie restriction for long-term remission of type 2 diabetes. Clinical Medicine. 2019, 19, 37–42. [Google Scholar] [CrossRef] [PubMed]
  6. Rajpal, A.; Ismail-Beigi, F. Intermittent fasting and 'metabolic switch': Effects on metabolic syndrome, prediabetes and type 2 diabetes. Diabetes Obes Metab. 2020, 22, 1496–1510. [Google Scholar] [CrossRef] [PubMed]
  7. Silva, A.I.; Direito, M.; Pinto-Ribeiro, F.; Ludovico, P.; Sampaio-Marques, B. Effects of Intermittent Fasting on Regulation of Metabolic Homeostasis: A Systematic Review and Meta-Analysis in Health and Metabolic-Related Disorders. Journal of Clinical Medicine. 2023, 12, 3699. [Google Scholar] [CrossRef] [PubMed]
  8. Kahleova, H.; Belinova, L.; Malinska, H.; Oliyarnyk, O.; Trnovska, J.; Skop, V.; et al. Eating two larger meals a day (breakfast and lunch) is more effective than six smaller meals in a reduced-energy regimen for patients with type 2 diabetes: a randomised crossover study. Diabetologia. 2014, 57, 1552–1560. [Google Scholar] [CrossRef] [PubMed]
  9. Ko, J.; Kimita, W.; Skudder-Hill, L.; Li, X.; Priya, S.; Bharmal, S.H.; et al. Dietary carbohydrate intake and insulin traits in individuals after acute pancreatitis: Effect modification by intra-pancreatic fat deposition. Pancreatology. 2021, 21, 353–362. [Google Scholar] [CrossRef] [PubMed]
  10. Niki, A.; Baden, M.Y.; Kato, S.; Mitsushio, K.; Horii, T.; Ozawa, H.; et al. Consumption of two meals per day is associated with increased intrapancreatic fat deposition in patients with type 2 diabetes: a retrospective study. BMJ Open Diabetes Res Care. 2022, 10. [Google Scholar] [CrossRef]
  11. Sami, W.; Ansari, T.; Butt, N.S.; Hamid, M.R.A. Effect of diet on type 2 diabetes mellitus: A review. Int J Health Sci 2017, 11, 65–71. [Google Scholar]
  12. Cienfuegos, S.; McStay, M.; Gabel, K.; Varady, K.A. Time restricted eating for the prevention of type 2 diabetes. J Physiol. 2022, 600, 1253–1264. [Google Scholar] [CrossRef] [PubMed]
  13. Harvie, M.N.; Pegington, M.; Mattson, M.P.; Frystyk, J.; Dillon, B.; Evans, G.; et al. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: a randomized trial in young overweight women. Int J Obes 2011, 35, 714–727. [Google Scholar] [CrossRef] [PubMed]
  14. Das, S.K.; Gilhooly, C.H.; Golden, J.K.; Pittas, A.G.; Fuss, P.J.; Cheatham, R.A.; et al. Long-term effects of 2 energy-restricted diets differing in glycemic load on dietary adherence, body composition, and metabolism in CALERIE: a 1-y randomized controlled trial. Am J Clin Nutr. 2007, 85, 1023–1030. [Google Scholar] [CrossRef] [PubMed]
  15. Varady, K.A.; Hellerstein, M.K. Alternate-day fasting and chronic disease prevention: a review of human and animal trials. Am J Clin Nutr. 2007, 86, 7–13. [Google Scholar] [CrossRef] [PubMed]
  16. Vasim, I.; Majeed, C.N.; DeBoer, M.D. Intermittent Fasting and Metabolic Health. Nutrients. 2022, 14. [Google Scholar] [CrossRef] [PubMed]
  17. Hajek, P.; Przulj, D.; Pesola, F.; McRobbie, H.; Peerbux, S.; Phillips-Waller, A.; et al. A randomised controlled trial of the 5:2 diet. PLoS One. 2021, 16, e0258853. [Google Scholar] [CrossRef] [PubMed]
  18. Aoun, A.; Ghanem, C.; Hamod, N.; Sawaya, S. The Safety and Efficacy of Intermittent Fasting for Weight Loss. Nutrition Today. 2020, 55, 270–277. [Google Scholar] [CrossRef]
  19. Kunduraci, Y.E.; Ozbek, H. Does the Energy Restriction Intermittent Fasting Diet Alleviate Metabolic Syndrome Biomarkers? A Randomized Controlled Trial. Nutrients. 2020, 12. [Google Scholar] [CrossRef]
  20. Chew, N.W.S.; Ng, C.H.; Tan, D.J.H.; Kong, G.; Lin, C.; Chin, Y.H.; et al. The global burden of metabolic disease: Data from 2000 to 2019. Cell Metab. 2023, 35, 414–428. [Google Scholar] [CrossRef]
  21. Chobot, A.; Górowska-Kowolik, K.; Sokołowska, M.; Jarosz-Chobot, P. Obesity and diabetes—Not only a simple link between two epidemics. Diabetes Metab. Res. Rev. 2018, 34, e3042. [Google Scholar] [CrossRef] [PubMed]
  22. Al-Sulaiti, H.; Diboun, I.; Agha, M.V.; Mohamed, F.F.S.; Atkin, S.; Domling, A.S.; et al. Metabolic signature of obesity-associated insulin resistance and type 2 diabetes. J Transl Med. 2019, 17, 348. [Google Scholar] [CrossRef] [PubMed]
  23. Jiang, S.Z.; Lu, W.; Zong, X.F.; Ruan, H.Y.; Liu, Y. Obesity and hypertension. Exp Ther Med. 2016, 12, 2395–2399. [Google Scholar] [CrossRef] [PubMed]
  24. Chooi, Y.C.; Ding, C.; Magkos, F. The epidemiology of obesity. Metabolism. 2019, 92, 6–10. [Google Scholar] [CrossRef] [PubMed]
  25. Pi-Sunyer, F.X. Obesity: criteria and classification. Proc Nutr Soc. 2000, 59, 505–509. [Google Scholar] [CrossRef] [PubMed]
  26. Zubrzycki, A.; Cierpka-Kmiec, K.; Kmiec, Z.; Wronska, A. The role of low-calorie diets and intermittent fasting in the treatment of obesity and type-2 diabetes. J Physiol Pharmacol. 2018, 69. [Google Scholar]
  27. Casanova, F.; Gooding, K.M.; Shore, A.C.; Adingupu, D.D.; Mawson, D.; Ball, C.; et al. Weight change and sulfonylurea therapy are related to 3 year change in microvascular function in people with type 2 diabetes. Diabetologia. 2020, 63, 1268–1278. [Google Scholar] [CrossRef] [PubMed]
  28. Catenacci, V.A.; Pan, Z.; Ostendorf, D.; Brannon, S.; Gozansky, W.S.; Mattson, M.P.; et al. A randomized pilot study comparing zero-calorie alternate-day fasting to daily caloric restriction in adults with obesity. Obesity 2016, 24, 1874–1883. [Google Scholar] [CrossRef]
  29. Chen, Z.; Li, G. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials. Clin Drug Investig. 2019, 39, 521–531. [Google Scholar] [CrossRef]
  30. de la Iglesia, R.; Loria-Kohen, V.; Zulet, M.A.; Martinez, J.A.; Reglero, G.; Ramirez de Molina, A. Dietary Strategies Implicated in the Prevention and Treatment of Metabolic Syndrome. Int J Mol Sci. 2016, 17. [Google Scholar] [CrossRef]
  31. Yuan, X.; Wang, J.; Yang, S.; Gao, M.; Cao, L.; Li, X.; et al. Effect of Intermittent Fasting Diet on Glucose and Lipid Metabolism and Insulin Resistance in Patients with Impaired Glucose and Lipid Metabolism: A Systematic Review and Meta-Analysis. Int J Endocrinol. 2022, 2022, 6999907. [Google Scholar] [CrossRef] [PubMed]
  32. Swiatkiewicz, I.; Wozniak, A.; Taub, P.R. Time-Restricted Eating and Metabolic Syndrome: Current Status and Future Perspectives. Nutrients. 2021, 13. [Google Scholar]
  33. Cui, Y.; Cai, T.; Zhou, Z.; Mu, Y.; Lu, Y.; Gao, Z.; et al. Health Effects of Alternate-Day Fasting in Adults: A Systematic Review and Meta-Analysis. Front Nutr. 2020, 7, 586036. [Google Scholar] [CrossRef] [PubMed]
  34. Gabel, K.; Kroeger, C.M.; Trepanowski, J.F.; Hoddy, K.K.; Cienfuegos, S.; Kalam, F.; Varady, K.A. Differential Effects of Alternate-Day Fasting Versus Daily Calorie Restriction on Insulin Resistance. Obesity 2019, 27, 1443–1450. [Google Scholar] [CrossRef]
  35. Arciero, P.J.; Poe, M.; Mohr, A.E.; Ives, S.J.; Arciero, A.; Sweazea, K.L.; et al. Intermittent fasting and protein pacing are superior to caloric restriction for weight and visceral fat loss. Obesity 2023, 31, 139–149. [Google Scholar] [CrossRef] [PubMed]
  36. Bilibio, B.L.E.; Dos Reis, W.R.; Compagnon, L.; de Batista, D.G.; Sulzbacher, L.M.; Pinheiro, J.F.; et al. Effects of alternate-day fasting and time-restricted feeding in obese middle-aged female rats. Nutrition. 2023, 116, 112198. [Google Scholar] [CrossRef]
  37. Che, T.; Yan, C.; Tian, D.; Zhang, X.; Liu, X.; Wu, Z. Time-restricted feeding improves blood glucose and insulin sensitivity in overweight patients with type 2 diabetes: a randomised controlled trial. Nutr Metab (Lond). 2021, 18, 88. [Google Scholar] [CrossRef]
  38. Yun, N.; Nah, J.; Lee, M.N.; Wu, D.; Pae, M. Post-Effects of Time-Restricted Feeding against Adipose Tissue Inflammation and Insulin Resistance in Obese Mice. Nutrients. 2023, 15, 2617. [Google Scholar] [CrossRef]
  39. Samuel, V.T.; Shulman, G.I. The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest. 2016, 126, 12–22. [Google Scholar] [CrossRef] [PubMed]
  40. Despres, J.P.; Lemieux, I. Abdominal obesity and metabolic syndrome. Nature. 2006, 444, 881–887. [Google Scholar] [CrossRef]
  41. Laakso, M.; Kuusisto, J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014, 10, 293–302. [Google Scholar] [CrossRef] [PubMed]
  42. Derakhshan, A.; Tohidi, M.; Arshi, B.; Khalili, D.; Azizi, F.; Hadaegh, F. Relationship of hyperinsulinaemia, insulin resistance and beta-cell dysfunction with incident diabetes and pre-diabetes: the Tehran Lipid and Glucose Study. Diabet Med. 2015, 32, 24–32. [Google Scholar] [CrossRef] [PubMed]
  43. Artasensi, A.; Pedretti, A.; Vistoli, G.; Fumagalli, L. Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules. 2020, 25. [Google Scholar] [CrossRef]
  44. Anton, S.D.; Moehl, K.; Donahoo, W.T.; Marosi, K.; Lee, S.A.; Mainous, A.G.; 3rd, et al. Flipping the Metabolic Switch: Understanding and Applying the Health Benefits of Fasting. Obesity 2018, 26, 254–268. [Google Scholar] [CrossRef] [PubMed]
  45. Collaboration NCDRF. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016, 387, 1513–1530. [Google Scholar] [CrossRef] [PubMed]
  46. Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019, 157, 107843. [Google Scholar] [CrossRef]
  47. Deshpande, A.D.; Harris-Hayes, M.; Schootman, M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008, 88, 1254–1264. [Google Scholar] [CrossRef] [PubMed]
  48. van Dieren, S.; Beulens, J.W.; van der Schouw, Y.T.; Grobbee, D.E.; Neal, B. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil. 2010, 17, S3–S8. [Google Scholar] [PubMed]
  49. Reaven, G.M. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: the price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrinol Metab Clin North Am. 2005, 34, 49–62. [Google Scholar] [CrossRef]
  50. Olefsky, J.M.; Farquhar, J.W.; Reaven, G.M. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med. 1974, 57, 551–560. [Google Scholar] [CrossRef]
  51. American Diabetes, A. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010, 33, S62–S69. [Google Scholar] [CrossRef]
  52. Ojo, T.K.; Joshua, O.O.; Ogedegbe, O.J.; Oluwole, O.; Ademidun, A.; Jesuyajolu, D. Role of Intermittent Fasting in the Management of Prediabetes and Type 2 Diabetes Mellitus. Cureus. 2022, 14, e28800. [Google Scholar] [CrossRef]
  53. Adeghate, E.; Schattner, P.; Dunn, E. An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci. 2006, 1084, 1–29. [Google Scholar] [CrossRef]
  54. Kalin, M.F.; Goncalves, M.; Fonseca, V. Pathogenesis of Type 2 Diabetes Mellitus. Principles of Diabetes Mellitus.
  55. Ozougwu, O. The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. Journal of Physiology and Pathophysiology. 2013, 4, 46–57. [Google Scholar] [CrossRef]
  56. Ghaffari, M.; Razi, S.; Zalpoor, H.; Nabi-Afjadi, M.; Mohebichamkhorami, F.; Zali, H. Association of MicroRNA-146a with Type 1 and 2 Diabetes and their Related Complications. J Diabetes Res. 2023, 2023, 2587104. [Google Scholar] [CrossRef]
  57. Kahkoska, A.R.; Dabelea, D. Diabetes in Youth: A Global Perspective. Endocrinol Metab Clin North Am. 2021, 50, 491–512. [Google Scholar] [CrossRef]
  58. Ali, O. Genetics of type 2 diabetes. World J Diabetes. 2013, 4, 114–123. [Google Scholar] [CrossRef]
  59. Ling, C.; Groop, L. Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes. 2009, 58, 2718–2725. [Google Scholar] [CrossRef]
  60. Yun, J.S.; Park, Y.M.; Cha, S.A.; Ahn, Y.B.; Ko, S.H. Progression of cardiovascular autonomic neuropathy and cardiovascular disease in type 2 diabetes. Cardiovasc Diabetol. 2018, 17, 109. [Google Scholar] [CrossRef]
  61. Shah, A.D.; Langenberg, C.; Rapsomaniki, E.; Denaxas, S.; Pujades-Rodriguez, M.; Gale, C.P.; et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015, 3, 105–113. [Google Scholar] [CrossRef]
  62. Shah, R.B.; Patel, M.; Maahs, D.M.; Shah, V.N. Insulin delivery methods: Past, present and future. Int J Pharm Investig. 2016, 6, 1–9. [Google Scholar] [CrossRef]
  63. Rys, P.; Wojciechowski, P.; Rogoz-Sitek, A.; Niesyczynski, G.; Lis, J.; Syta, A.; Malecki, M.T. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol. 2015, 52, 649–662. [Google Scholar] [CrossRef]
  64. Nathan, D.M.; Buse, J.B.; Davidson, M.B.; Ferrannini, E.; Holman, R.R.; Sherwin, R.; et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009, 32, 193–203. [Google Scholar] [CrossRef]
  65. Clissold, R.; Clissold, S. Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value. Core Evid. 2007, 2, 89–110. [Google Scholar] [CrossRef]
  66. Hajos, T.R.; Pouwer, F.; de Grooth, R.; Holleman, F.; Twisk, J.W.; Diamant, M.; Snoek, F.J. Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care. Diabet Med. 2011, 28, 1096–1102. [Google Scholar] [CrossRef]
  67. Wang, Z.; Hedrington, M.S.; Gogitidze Joy, N.; Briscoe, V.J.; Richardson, M.A.; Younk, L.; et al. Dose-response effects of insulin glargine in type 2 diabetes. Diabetes Care. 2010, 33, 1555–1560. [Google Scholar] [CrossRef]
  68. El-Zayat, S.R.; Sibaii, H.; El-Shamy, K.A. Physiological process of fat loss. Bulletin of the National Research Centre. 2019, 43. [Google Scholar] [CrossRef]
  69. Davies, M.; Khunti, K. Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine. Diabetes Obes. Metab. 2008, 10, 42–49. [Google Scholar] [CrossRef]
  70. Lund, A.; Knop, F.K.; Vilsboll, T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med. 2014, 25, 407–414. [Google Scholar] [CrossRef]
  71. Baggio, L.L.; Drucker, D.J. Biology of Incretins: GLP-1 and, G. I.P. Gastroenterology. 2007, 132, 2131–2157. [Google Scholar] [CrossRef]
  72. Ajabnoor, G.M.A.; Hashim, K.T.; Alzahrani, M.M.; Alsuheili, A.Z.; Alharbi, A.F.; Alhozali, A.M.; et al. The Possible Effect of the Long-Term Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Hba1c and Lipid Profile in Type 2 Diabetes Mellitus: A Retrospective Study in KAUH, Jeddah, Saudi Arabia. Diseases. 2023, 11, 50. [Google Scholar] [CrossRef]
  73. Tofé, S.; Argüelles, I.; Mena, E.; Serra, G.; Codina, M.; Urgeles, J.R.; et al. Real-world GLP-1 RA therapy in type 2 diabetes: A long-term effectiveness observational study. Endocrinol. Diabetes Metab. 2019, 2, e00051. [Google Scholar] [CrossRef]
  74. Kaneto, H.; Kimura, T.; Shimoda, M.; Obata, A.; Sanada, J.; Fushimi, Y.; et al. Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: “The Earlier, the Better” in Therapy with Incretin-Based Medicine. International Journal of Molecular Sciences. 2021, 22, 7917. [Google Scholar] [CrossRef]
  75. Lee, S.; Lee, D.Y. Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Ann Pediatr Endocrinol Metab. 2017, 22, 15–26. [Google Scholar] [CrossRef]
  76. Bettge, K.; Kahle, M.; Abd El Aziz, M.S.; Meier, J.J.; Nauck, M.A. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab. 2017, 19, 336–347. [Google Scholar] [CrossRef]
  77. Gether, I.M.; Nexoe-Larsen, C.; Knop, F.K. New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs. J Clin Endocrinol Metab. 2019, 104, 2463–2472. [Google Scholar] [CrossRef]
  78. Deacon, C.F. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020, 16, 642–653. [Google Scholar] [CrossRef]
  79. Solis-Herrera, C.; Triplitt, C.; Garduno-Garcia Jde, J.; Adams, J.; DeFronzo, R.A.; Cersosimo, E. Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study. Diabetes Care. 2013, 36, 2756–2762. [Google Scholar] [CrossRef]
  80. Goldstein, B.J.; Feinglos, M.N.; Lunceford, J.K.; Johnson, J.; Williams-Herman, D.E. Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes. Diabetes Care. 2007, 30, 1979–1987. [Google Scholar] [CrossRef]
  81. Scheen, A.J. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf. 2015, 14, 505–524. [Google Scholar] [CrossRef]
  82. Santos, L.L.; Lima, F.J.C.; Sousa-Rodrigues, C.F.; Barbosa, F.T. Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus. Rev Assoc Med Bras 2017, 63, 636–641. [Google Scholar] [CrossRef]
  83. Pinto, L.C.; Rados, D.V.; Remonti, L.R.; Kramer, C.K.; Leitao, C.B.; Gross, J.L. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Diabetol. Metab. Syndr. 2015, 7, A58. [Google Scholar] [CrossRef]
  84. Colosimo, S.; Tan, G.D.; Petroni, M.L.; Marchesini, G.; Tomlinson, J.W. Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent. Nutr. Metab. Cardiovasc. Dis. 2023, 33, 640–648. [Google Scholar] [CrossRef]
  85. Shigiyama, F.; Kumashiro, N.; Miyagi, M.; Ikehara, K.; Kanda, E.; Uchino, H.; Hirose, T. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovascular Diabetology. 2017, 16. [Google Scholar] [CrossRef]
  86. Satoh, H. Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control. Diabetology International. 2018, 9, 212–214. [Google Scholar] [CrossRef]
  87. Gill, H.K.; Kaur, P.; Mahendru, S.; Mithal, A. Adverse Effect Profile and Effectiveness of Sodium Glucose Co-transporter 2 Inhibitors (SGLT2i) - A Prospective Real-world Setting Study. Indian J Endocrinol Metab. 2019, 23, 50–55. [Google Scholar]
  88. Wang, G.S.; Hoyte, C. Review of Biguanide (Metformin) Toxicity. J Intensive Care Med. 2019, 34, 863–876. [Google Scholar] [CrossRef]
  89. He, L. Metformin and Systemic Metabolism. Trends Pharmacol Sci. 2020, 41, 868–881. [Google Scholar] [CrossRef]
  90. Horakova, O.; Kroupova, P.; Bardova, K.; Buresova, J.; Janovska, P.; Kopecky, J.; Rossmeisl, M. Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport. Scientific Reports. 2019, 9. [Google Scholar] [CrossRef]
  91. McCreight, L.J.; Bailey, C.J.; Pearson, E.R. Metformin and the gastrointestinal tract. Diabetologia. 2016, 59, 426–435. [Google Scholar] [CrossRef]
  92. Wakeman, M.; Archer, D.T. Metformin and Micronutrient Status in Type 2 Diabetes: Does Polypharmacy Involving Acid-Suppressing Medications Affect Vitamin B12 Levels? Diabetes Metab Syndr Obes. 2020, 13, 2093–2108. [Google Scholar] [CrossRef]
  93. Kozyraki, R.; Cases, O. Vitamin B12 absorption: mammalian physiology and acquired and inherited disorders. Biochimie. 2013, 95, 1002–1007. [Google Scholar] [CrossRef]
  94. Gong, Q.; Zhang, P.; Wang, J.; Ma, J.; An, Y.; Chen, Y.; et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019, 7, 452–461. [Google Scholar] [CrossRef]
  95. The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention. Diabetes Care. 2012, 35, 723–730. [CrossRef]
  96. Diabetes Prevention Program Research, G.; Knowler, W.C.; Fowler, S.E.; Hamman, R.F.; Christophi, C.A.; Hoffman, H.J.; et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009, 374, 1677–1686. [Google Scholar] [CrossRef]
  97. Cardona-Morrell, M.; Rychetnik, L.; Morrell, S.L.; Espinel, P.T.; Bauman, A. Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis. BMC Public Health. 2010, 10, 653. [Google Scholar] [CrossRef]
  98. Lean, M.E.J. Banting Memorial Lecture 2021—Banting, banting, banter and bravado: Convictions meet evidence in the scientific process. Diabetic Medicine. 2021, 38. [Google Scholar] [CrossRef]
  99. Hartman, A.L.; Vining, E.P.G. Clinical Aspects of the Ketogenic Diet. Epilepsia. 2007, 48, 31–42. [Google Scholar] [CrossRef]
  100. Ortega, R. Importance of functional foods in the Mediterranean diet. Public Health Nutrition. 2006, 9, 1136–1140. [Google Scholar] [CrossRef]
  101. Kossoff, E.H.; McGrogan, J.R. Worldwide Use of the Ketogenic Diet. Epilepsia. 2005, 46, 280–289. [Google Scholar] [CrossRef]
  102. Jakubowicz, D.; Froy, O.; Wainstein, J.; Boaz, M. Meal timing and composition influence ghrelin levels, appetite scores and weight loss maintenance in overweight and obese adults. Steroids. 2012, 77, 323–331. [Google Scholar] [CrossRef]
  103. Taylor, R. Banting Memorial Lecture 2012 Reversing the twin cycles of Type 2 diabetes. Diabetic Medicine. 2013, 30, 267–275. [Google Scholar] [CrossRef]
  104. Yancy, W.S.; Foy, M.; Chalecki, A.M.; Vernon, M.C.; Westman, E.C. A low-carbohydrate, ketogenic diet to treat type 2 diabetes. Nutrition & Metabolism. 2005, 2, 34. [Google Scholar] [CrossRef]
  105. Koloverou, E.; Esposito, K.; Giugliano, D.; Panagiotakos, D. The effect of Mediterranean diet on the development of type 2 diabetes mellitus: a meta-analysis of 10 prospective studies and 136,846 participants. Metabolism. 2014, 63, 903–911. [Google Scholar] [CrossRef]
  106. Bao, W.; Tobias, D.K.; Bowers, K.; Chavarro, J.; Vaag, A.; Grunnet, L.G.; et al. Physical Activity and Sedentary Behaviors Associated With Risk of Progression From Gestational Diabetes Mellitus to Type 2 Diabetes Mellitus. JAMA Internal Medicine. 2014, 174, 1047. [Google Scholar] [CrossRef]
  107. Hrubeniuk, T.J.; Bouchard, D.R.; Goulet, E.D.B.; Gurd, B.; Senechal, M. The ability of exercise to meaningfully improve glucose tolerance in people living with prediabetes: A meta-analysis. Scand J Med Sci Sports. 2020, 30, 209–216. [Google Scholar] [CrossRef]
  108. Agboola, S.; Jethwani, K.; Lopez, L.; Searl, M.; O'Keefe, S.; Kvedar, J. Text to Move: A Randomized Controlled Trial of a Text-Messaging Program to Improve Physical Activity Behaviors in Patients With Type 2 Diabetes Mellitus. J Med Internet Res. 2016, 18, e307. [Google Scholar] [CrossRef]
  109. Hansen, D.; Dendale, P.; Jonkers, R.A.M.; Beelen, M.; Manders, R.J.F.; Corluy, L.; et al. Continuous low- to moderate-intensity exercise training is as effective as moderate- to high-intensity exercise training at lowering blood HbA1c in obese type 2 diabetes patients. Diabetologia. 2009, 52, 1789–1797. [Google Scholar] [CrossRef]
  110. Medagama, A.; Galgomuwa, M. Lack of infrastructure, social and cultural factors limit physical activity among patients with type 2 diabetes in rural Sri Lanka, a qualitative study. PLOS ONE. 2018, 13, e0192679. [Google Scholar] [CrossRef]
  111. Trepanowski, J.F.; Kroeger, C.M.; Barnosky, A.; Klempel, M.C.; Bhutani, S.; Hoddy, K.K.; et al. Effect of Alternate-Day Fasting on Weight Loss, Weight Maintenance, and Cardioprotection Among Metabolically Healthy Obese Adults. JAMA Internal Medicine. 2017, 177, 930. [Google Scholar] [CrossRef] [PubMed]
  112. Barnosky, A.R.; Hoddy, K.K.; Unterman, T.G.; Varady, K.A. Intermittent fasting vs daily calorie restriction for type 2 diabetes prevention: a review of human findings. Transl Res. 2014, 164, 302–311. [Google Scholar] [CrossRef]
  113. Xu, S.; Jiang, Y.; Zhang, Y.; Xu, W.; Zhang, H.; Yan, Q.; et al. Dietary recommendations for fasting days in an alternate-day intermittent fasting pattern: A randomized controlled trial. Nutrition. 2022, 102, 111735. [Google Scholar] [CrossRef]
  114. Varady, K.A. Intermittent versus daily calorie restriction: which diet regimen is more effective for weight loss? Obesity Reviews. 2011, 12, e593–e601. [Google Scholar] [CrossRef]
  115. Cai, H. ; Qin Y-L, Shi Z-Y, Chen J-H, Zeng, M.-J.; Zhou, W.; et al. Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: a randomised controlled trial. BMC Gastroenterology.
  116. Heilbronn, L.K.; Civitarese, A.E.; Bogacka, I.; Smith, S.R.; Hulver, M.; Ravussin, E. Glucose Tolerance and Skeletal Muscle Gene Expression in Response to Alternate Day Fasting. Obesity Research. 2005, 13, 574–581. [Google Scholar] [CrossRef]
  117. Higashida, K.; Fujimoto, E.; Higuchi, M.; Terada, S. Effects of alternate-day fasting on high-fat diet-induced insulin resistance in rat skeletal muscle. Life Sci. 2013, 93, 208–213. [Google Scholar] [CrossRef]
  118. Swoap, S.J.; Bingaman, M.J.; Hult, E.M.; Sandstrom, N.J. Alternate-day feeding leads to improved glucose regulation on fasting days without significant weight loss in genetically obese mice. Am. J. Physiol. -Regul. Integr. Comp. Physiol. 2019, 317, R461–R9. [Google Scholar] [CrossRef]
  119. Beigy, M.; Vakili, S.; Berijani, S.; Aminizade, M.; Ahmadi-Dastgerdi, M.; Meshkani, R. Alternate-day fasting diet improves fructose-induced insulin resistance in mice. Journal of Animal Physiology and Animal Nutrition. 2013, 97, 1125–1131. [Google Scholar] [CrossRef]
  120. Ingersen, A.; Helset, H.R.; Calov, M.; Chabanova, E.; Harreskov, E.G.; Jensen, C.; et al. Metabolic effects of alternate-day fasting in males with obesity with or without type 2 diabetes. Frontiers in Physiology. 2022, 13. [Google Scholar] [CrossRef]
  121. Gabel, K.; Kroeger, C.M.; Trepanowski, J.F.; Hoddy, K.K.; Cienfuegos, S.; Kalam, F.; Varady, K.A. Differential Effects of Alternate-Day Fasting Versus Daily Calorie Restriction on Insulin Resistance. Obesity. 2019, 27, 1443–1450. [Google Scholar] [CrossRef]
  122. De Cabo, R.; Mattson, M.P. Effects of Intermittent Fasting on Health, Aging, and Disease. New England Journal of Medicine. 2019, 381, 2541–2551. [Google Scholar] [CrossRef]
  123. Kroeger, C.M.; Trepanowski, J.F.; Klempel, M.C.; Barnosky, A.; Bhutani, S.; Gabel, K.; Varady, K.A. Eating behavior traits of successful weight losers during 12 months of alternate-day fasting: An exploratory analysis of a randomized controlled trial. Nutrition and Health. 2018, 24, 5–10. [Google Scholar] [CrossRef] [PubMed]
  124. Kalam, F.; Gabel, K.; Cienfuegos, S.; Wiseman, E.; Ezpeleta, M.; Pavlou, V.; Varady, K.A. Changes in subjective measures of appetite during 6 months of alternate day fasting with a low carbohydrate diet. Clin Nutr ESPEN. 2021, 41, 417–422. [Google Scholar] [CrossRef] [PubMed]
  125. Carter, S.; Clifton, P.M.; Keogh, J.B. The effects of intermittent compared to continuous energy restriction on glycaemic control in type 2 diabetes; a pragmatic pilot trial. Diabetes Res Clin Pract. 2016, 122, 106–112. [Google Scholar] [CrossRef] [PubMed]
  126. Lim, E.L.; Hollingsworth, K.G.; Aribisala, B.S.; Chen, M.J.; Mathers, J.C.; Taylor, R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011, 54, 2506–2514. [Google Scholar] [CrossRef] [PubMed]
  127. Corley, B.T.; Carroll, R.W.; Hall, R.M.; Weatherall, M.; Parry-Strong, A.; Krebs, J.D. Intermittent fasting in Type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial. Diabetic Medicine. 2018, 35, 588–594. [Google Scholar] [CrossRef] [PubMed]
  128. Carter, S.; Clifton, P.M.; Keogh, J.B. Intermittent energy restriction in type 2 diabetes: A short discussion of medication management. World J Diabetes. 2016, 7, 627–630. [Google Scholar] [CrossRef]
  129. Baker, S.; Jerums, G.; Proietto, J. Effects and clinical potential of very-low-calorie diets (VLCDs) in type 2 diabetes. Diabetes Res Clin Pract. 2009, 85, 235–242. [Google Scholar] [CrossRef] [PubMed]
  130. Cook, F.; Langdon-Daly, J.; Serpell, L. Compliance of participants undergoing a ‘5-2’ intermittent fasting diet and impact on body weight. Clinical Nutrition ESPEN. 2022, 52, 257–261. [Google Scholar] [CrossRef]
  131. Wu, B.; White, K.; Maw, M.T.T.; Charleston, J.; Zhao, D.; Guallar, E.; et al. Adherence to Diet and Meal Timing in a Randomized Controlled Feeding Study of Time-Restricted Feeding. Nutrients. 2022, 14, 2283. [Google Scholar] [CrossRef]
  132. Hutchison, A.T.; Regmi, P.; Manoogian, E.N.C.; Fleischer, J.G.; Wittert, G.A.; Panda, S.; Heilbronn, L.K. Time-Restricted Feeding Improves Glucose Tolerance in Men at Risk for Type 2 Diabetes: A Randomized Crossover Trial. Obesity. 2019, 27, 724–732. [Google Scholar] [CrossRef]
  133. de Goede, P.; Foppen, E.; Ritsema, W.; Korpel, N.L.; Yi, C.X.; Kalsbeek, A. Time-Restricted Feeding Improves Glucose Tolerance in Rats, but Only When in Line With the Circadian Timing System. Front Endocrinol (Lausanne). 2019, 10, 554. [Google Scholar] [CrossRef]
  134. Lynch, S.; Johnston, J.D.; Robertson, M.D. Early versus late time-restricted feeding in adults at increased risk of developing type 2 diabetes: Is there an optimal time to eat for metabolic health? Nutrition Bulletin. 2021, 46, 69–76. [Google Scholar] [CrossRef]
  135. Lowe, D.A.; Wu, N.; Rohdin-Bibby, L.; Moore, A.H.; Kelly, N.; Liu, Y.E.; et al. Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity. JAMA Internal Medicine. 2020, 180, 1491. [Google Scholar] [CrossRef]
  136. Parr, E.B.; Devlin, B.L.; Radford, B.E.; Hawley, J.A. A Delayed Morning and Earlier Evening Time-Restricted Feeding Protocol for Improving Glycemic Control and Dietary Adherence in Men with Overweight/Obesity: A Randomized Controlled Trial. Nutrients. 2020, 12. [Google Scholar] [CrossRef] [PubMed]
  137. Tsameret, S.; Chapnik, N.; Froy, O. Effect of early vs. late time-restricted high-fat feeding on circadian metabolism and weight loss in obese mice. Cellular and Molecular Life Sciences.
  138. Perreault, L.; Pan, Q.; Mather, K.J.; Watson, K.E.; Hamman, R.F.; Kahn, S.E.; Diabetes Prevention Program Research, G. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012, 379, 2243–2251. [Google Scholar] [CrossRef]
  139. Abraham, T.M.; Fox, C.S. Implications of rising prediabetes prevalence. Diabetes Care. 2013, 36, 2139–2141. [Google Scholar] [CrossRef]
  140. Gong, R.; Liu, Y.; Luo, G.; Liu, W.; Jin, Z.; Xu, Z.; et al. Associations of TG/HDL Ratio with the Risk of Prediabetes and Diabetes in Chinese Adults: A Chinese Population Cohort Study Based on Open Data. Int J Endocrinol. 2021, 2021, 9949579. [Google Scholar] [CrossRef]
  141. Brannick, B.; Wynn, A.; Dagogo-Jack, S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp Biol Med (Maywood). 2016, 241, 1323–1331. [Google Scholar] [CrossRef] [PubMed]
  142. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2013, 36, S67–S74. [CrossRef]
  143. Rooney, M.R.; Fang, M.; Ogurtsova, K.; Ozkan, B.; Echouffo-Tcheugui, J.B.; Boyko, E.J.; et al. Global Prevalence of Prediabetes. Diabetes Care. 2023, 46, 1388–1394. [Google Scholar] [CrossRef]
  144. Lomonaco, R.; Ortiz-Lopez, C.; Orsak, B.; Webb, A.; Hardies, J.; Darland, C.; et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology. 2012, 55, 1389–1397. [Google Scholar] [CrossRef] [PubMed]
  145. Rattarasarn, C. Dysregulated lipid storage and its relationship with insulin resistance and cardiovascular risk factors in non-obese Asian patients with type 2 diabetes. Adipocyte. 2018, 7, 71–80. [Google Scholar] [CrossRef] [PubMed]
  146. Sugimoto, D.; Tamura, Y.; Takeno, K.; Kaga, H.; Someya, Y.; Kakehi, S.; et al. Clinical Features of Nonobese, Apparently Healthy, Japanese Men With Reduced Adipose Tissue Insulin Sensitivity. J Clin Endocrinol Metab. 2019, 104, 2325–2333. [Google Scholar] [CrossRef] [PubMed]
  147. Kim, J.Y.; Bacha, F.; Tfayli, H.; Michaliszyn, S.F.; Yousuf, S.; Arslanian, S. Adipose Tissue Insulin Resistance in Youth on the Spectrum From Normal Weight to Obese and From Normal Glucose Tolerance to Impaired Glucose Tolerance to Type 2 Diabetes. Diabetes Care. 2019, 42, 265–272. [Google Scholar] [CrossRef] [PubMed]
  148. Salazar, M.R.; Carbajal, H.A.; Espeche, W.G.; Aizpurúa, M.; Leiva Sisnieguez, C.E.; Leiva Sisnieguez, B.C.; et al. Insulin resistance: The linchpin between prediabetes and cardiovascular disease. Diabetes and Vascular Disease Research. 2016, 13, 157–163. [Google Scholar] [CrossRef]
  149. Gayoso-Diz, P.; Otero-González, A.; Rodriguez-Alvarez, M.X.; Gude, F.; García, F.; De Francisco, A.; Quintela, A.G. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. BMC Endocrine Disorders. 2013, 13, 47. [Google Scholar] [CrossRef]
  150. Guemes, M.; Rahman, S.A.; Hussain, K. What is a normal blood glucose? Arch Dis Child. 2016, 101, 569–574. [Google Scholar] [CrossRef]
  151. Gerstein, H.C.; Santaguida, P.; Raina, P.; Morrison, K.M.; Balion, C.; Hunt, D.; et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007, 78, 305–312. [Google Scholar] [CrossRef] [PubMed]
  152. Echouffo-Tcheugui, J.B.; Perreault, L.; Ji, L.; Dagogo-Jack, S. Diagnosis and Management of Prediabetes: A Review. JAMA. 2023, 329, 1206–1216. [Google Scholar] [CrossRef]
  153. Saito, T. Lifestyle Modification and Prevention of Type 2 Diabetes in Overweight Japanese With Impaired Fasting Glucose Levels. Archives of Internal Medicine. 2011, 171, 1352. [Google Scholar] [CrossRef]
  154. Reasner, C.; Olansky, L.; Seck, T.L.; Williams-Herman, D.E.; Chen, M.; Terranella, L.; et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 2011, 13, 644–652. [Google Scholar] [CrossRef]
  155. Ding, Y.; Liu, Y.; Qu, Y.; Lin, M.; Dong, F.; Li, Y.; et al. Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus therapy: a meta-analysis. Eur Rev Med Pharmacol Sci. 2022, 26, 2802–2817. [Google Scholar] [PubMed]
  156. Terada, T.; Boule, N.G. Does metformin therapy influence the effects of intensive lifestyle intervention? Exploring the interaction between first line therapies in the Look AHEAD trial. Metabolism. 2019, 94, 39–46. [Google Scholar] [CrossRef] [PubMed]
  157. Rana, J.S.; Li, T.Y.; Manson, J.E.; Hu, F.B. Adiposity Compared With Physical Inactivity and Risk of Type 2 Diabetes in Women. Diabetes Care. 2007, 30, 53–58. [Google Scholar] [CrossRef]
  158. Hamasaki, H. Daily physical activity and type 2 diabetes: A review. World J Diabetes. 2016, 7, 243–251. [Google Scholar] [CrossRef]
  159. Holloszy, J.O. Exercise-induced increase in muscle insulin sensitivity. J Appl Physiol 2005, 99, 338–343. [Google Scholar] [CrossRef]
  160. Hrubeniuk, T.J.; Bouchard, D.R.; Goulet, E.D.B.; Gurd, B.; Sénéchal, M. The ability of exercise to meaningfully improve glucose tolerance in people living with prediabetes: A meta-analysis. Scandinavian Journal of Medicine & Science in Sports. 2020, 30, 209–216. [Google Scholar] [CrossRef] [PubMed]
  161. Chen, A.K.; Roberts, C.K.; Barnard, R.J. Effect of a short-term diet and exercise intervention on metabolic syndrome in overweight children. Metabolism. 2006, 55, 871–878. [Google Scholar] [CrossRef] [PubMed]
  162. Durstine, J.L. Effect of aerobic exercise on high-density lipoprotein cholesterol: a meta-analysis. Clin J Sport Med. 2008, 18, 107–108. [Google Scholar] [CrossRef]
  163. Kodama, S.; Tanaka, S.; Saito, K.; Shu, M.; Sone, Y.; Onitake, F.; et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: a meta-analysis. Arch Intern Med. 2007, 167, 999–1008. [Google Scholar] [CrossRef]
  164. Janssen, S.M.; Connelly, D.M. The effects of exercise interventions on physical function tests and glycemic control in adults with type 2 diabetes: A systematic review. J Bodyw Mov Ther. 2021, 28, 283–293. [Google Scholar] [CrossRef]
  165. Magkos, F.; Hjorth, M.F.; Astrup, A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology. 2020, 16, 545–555. [Google Scholar] [CrossRef]
  166. Wei, J.; Chen, J.; Wei, X.; Xiang, X.; Cheng, Q.; Xu, J.; et al. Long-term remission of type 2 diabetes after very-low-calorie restriction and related predictors. Frontiers in Endocrinology. 2022, 13. [Google Scholar] [CrossRef]
  167. McAndrew, L.M.; Napolitano, M.A.; Pogach, L.M.; Quigley, K.S.; Shantz, K.L.; Vander Veur, S.S.; Foster, G.D. The impact of self-monitoring of blood glucose on a behavioral weight loss intervention for patients with type 2 diabetes. Diabetes Educ. 2013, 39, 397–405. [Google Scholar] [CrossRef]
  168. Thom, G.; McIntosh, A.; Messow, C.M.; Leslie, W.S.; Barnes, A.C.; Brosnahan, N.; et al. Weight loss-induced increase in fasting ghrelin concentration is a predictor of weight regain: Evidence from the Diabetes Remission Clinical Trial (DiRECT). Diabetes Obes Metab. 2021, 23, 711–719. [Google Scholar] [CrossRef]
  169. Sutton, E.F.; Beyl, R.; Early, K.S.; Cefalu, W.T.; Ravussin, E.; Peterson, C.M. Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes. Cell Metabolism. 2018, 27, 1212–1221. [Google Scholar] [CrossRef]
  170. Nowosad, K.; Sujka, M. Effect of Various Types of Intermittent Fasting (IF) on Weight Loss and Improvement of Diabetic Parameters in Human. Curr Nutr Rep. 2021, 10, 146–154. [Google Scholar] [CrossRef]
  171. Li, M.; Li, J.; Xu, Y.; Gao, J.; Cao, Q.; Ding, Y.; et al. Effect of 5, 2 Regimens: Energy-Restricted Diet or Low-Volume High-Intensity Interval Training Combined With Resistance Exercise on Glycemic Control and Cardiometabolic Health in Adults With Overweight/Obesity and Type 2 Diabetes-A Three-Arm Randomized Controlled Trial. Diabetes Care. 2024.
  172. Gabel, K.; Hoddy, K.K.; Haggerty, N.; Song, J.; Kroeger, C.M.; Trepanowski, J.F.; et al. Effects of 8-hour time restricted feeding on body weight and metabolic disease risk factors in obese adults: A pilot study. Nutrition and Healthy Aging. 2018, 4, 345–353. [Google Scholar] [CrossRef]
  173. Wilkinson, M.J.; Manoogian, E.N.C.; Zadourian, A.; Lo, H.; Fakhouri, S.; Shoghi, A.; et al. Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome. Cell Metab. 2020, 31, 92–104. [Google Scholar] [CrossRef]
  174. Tinsley, G.M.; La Bounty, P.M. Effects of intermittent fasting on body composition and clinical health markers in humans. Nutrition Reviews. 2015, 73, 661–674. [Google Scholar] [CrossRef]
  175. Cienfuegos, S.; McStay, M.; Gabel, K.; Varady, K.A. Time restricted eating for the prevention of type 2 diabetes. The Journal of Physiology. 2022, 600, 1253–1264. [Google Scholar] [CrossRef]
  176. Martens, C.R.; Rossman, M.J.; Mazzo, M.R.; Jankowski, L.R.; Nagy, E.E.; Denman, B.A.; et al. Short-term time-restricted feeding is safe and feasible in non-obese healthy midlife and older adults. GeroScience. 2020, 42, 667–686. [Google Scholar] [CrossRef]
  177. Tsitsou, S.; Zacharodimos, N.; Poulia, K.A.; Karatzi, K.; Dimitriadis, G.; Papakonstantinou, E. Effects of Time-Restricted Feeding and Ramadan Fasting on Body Weight, Body Composition, Glucose Responses, and Insulin Resistance: A Systematic Review of Randomized Controlled Trials. Nutrients. 2022, 14. [Google Scholar] [CrossRef]
  178. Andriessen, C.; Fealy, C.E.; Veelen, A.; van Beek, S.M.M.; Roumans, K.H.M.; Connell, N.J.; et al. Three weeks of time-restricted eating improves glucose homeostasis in adults with type 2 diabetes but does not improve insulin sensitivity: a randomised crossover trial. Diabetologia. 2022, 65, 1710–1720. [Google Scholar] [CrossRef]
  179. Che, T.; Yan, C.; Tian, D.; Zhang, X.; Liu, X.; Wu, Z. Time-restricted feeding improves blood glucose and insulin sensitivity in overweight patients with type 2 diabetes: a randomised controlled trial. Nutrition & Metabolism.
  180. Ravussin, E.; Beyl, R.A.; Poggiogalle, E.; Hsia, D.S.; Peterson, C.M. Early Time-Restricted Feeding Reduces Appetite and Increases Fat Oxidation But Does Not Affect Energy Expenditure in Humans. Obesity. 2019, 27, 1244–1254. [Google Scholar] [CrossRef]
  181. Bandin, C.; Scheer, F.A.; Luque, A.J.; Avila-Gandia, V.; Zamora, S.; Madrid, J.A.; et al. Meal timing affects glucose tolerance, substrate oxidation and circadian-related variables: A randomized, crossover trial. Int J Obes (Lond). 2015, 39, 828–833. [Google Scholar] [CrossRef]
  182. Garaulet, M.; Gomez-Abellan, P.; Alburquerque-Bejar, J.J.; Lee, Y.C.; Ordovas, J.M.; Scheer, F.A. Timing of food intake predicts weight loss effectiveness. Int J Obes (Lond). 2013, 37, 604–611. [Google Scholar] [CrossRef]
  183. Jakubowicz, D.; Barnea, M.; Wainstein, J.; Froy, O. High Caloric intake at breakfast vs. dinner differentially influences weight loss of overweight and obese women. Obesity. 2013, 21, 2504–2512. [Google Scholar] [CrossRef]
  184. Allison, K.C.; Hopkins, C.M.; Ruggieri, M.; Spaeth, A.M.; Ahima, R.S.; Zhang, Z.; et al. Prolonged, Controlled Daytime versus Delayed Eating Impacts Weight and Metabolism. Current Biology. 2021, 31, 650–657. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.

Downloads

157

Views

83

Comments

0

Subscription

Notify me about updates to this article or when a peer-reviewed version is published.

Email

Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2025 MDPI (Basel, Switzerland) unless otherwise stated